

-continued

Tyr	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Ser	Ser	Pro	Lys	Pro	Trp	Ile	Tyr
		35					40					45			
Arg	Thr	Ser	Asn	Leu	Ala	Ser	Gly	Val	Pro	Ala	Arg	Phe	Ser	Gly	Ser
	50					55					60				
Gly	Ser	Gly	Thr	Ser	Tyr	Ser	Leu	Thr	Ile	Ser	Ser	Met	Glu	Ala	Glu
65				70					75						80
Asp	Ala	Ala	Thr	Tyr	Tyr	Cys	Gln	Leu	Tyr	His	Ser	Tyr	Pro	Pro	Thr
			85						90					95	
Trp	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys				
			100				105								

1. An anti-IL-25 antibody that (i) competes with murine antibody 18H3 for binding to (human) IL-25; and/or (ii) binds to the same epitope on (human) IL-25 as 18H3; and/or (iii) cross-blocks the binding of 18H3 to (human) IL-25.

2. The anti-IL-25 antibody according to claim 1, wherein the antibody comprises a heavy chain variable region and a light chain variable region, in which the heavy chain variable region comprises:

- a) a CDR1 which comprises or essentially consists of either (i) the amino acid sequence GFSLSSTSGMGLG (SEQ ID NO: 1) or (ii) an amino acid sequence that has only 3, 2 or 1 amino acid difference(s) with the amino acid sequence GFSLSSTSGMGLG (SEQ ID NO: 1);
- b) a CDR2 which comprises or essentially consists of either (i) the amino acid sequence HIWWDDVKHYKPALKS (SEQ ID NO: 2) or (ii) an amino acid sequence that has only 3, 2 or 1 amino acid difference(s) with the amino acid sequence HIWWDDVKHYKPALKS (SEQ ID NO: 2); and
- c) a CDR3 which comprises or essentially consists of either (i) the amino acid sequence MGQLHYGYDYAMDY (SEQ ID NO: 3) or (ii) an amino acid sequence that has only 3, 2 or 1 amino acid difference(s) with the amino acid sequence MGQLHYGYDYAMDY (SEQ ID NO: 3);

and

in which the light chain variable region comprises:

- a) a CDR1 which comprises or essentially consists of either (i) the amino acid sequence SASSSVSYMY (SEQ ID NO: 4) or (ii) an amino acid sequence that has only 3, 2 or 1 amino acid difference(s) with the amino acid sequence SASSSVSYMY (SEQ ID NO: 4);
- b) a CDR2 which comprises or essentially consists of either (i) the amino acid sequence RTSNLAS (SEQ ID NO: 5) or (ii) an amino acid sequence that has only 3, 2 or 1 amino acid difference(s) with the amino acid sequence RTSNLAS (SEQ ID NO: 5); and
- c) a CDR3 which comprises or essentially consists of either (i) the amino acid sequence QLYHSYPPTWT (SEQ ID NO: 6) or (ii) an amino acid sequence that has only 3, 2 or 1 amino acid difference(s) with the amino acid sequence QLYHSYPPTWT (SEQ ID NO: 6).

3. The anti-IL-25 antibody according to claim 2, wherein the heavy chain variable region comprises a CDR1 having the amino acid sequence GFSLSSTSGMGLG (SEQ ID NO: 1), a CDR2 having the amino acid sequence HIWWDDVKHYKPALKS (SEQ ID NO: 2) and a CDR3 having the amino acid sequence MGQLHYGYDYAMDY (SEQ ID NO: 3), and the light chain variable region comprises a CDR1 having the amino acid sequence SASSSVSYMY (SEQ ID NO: 4), a CDR2 having the amino

acid sequence RTSNLAS (SEQ ID NO: 5) and a CDR3 having the amino acid sequence QLYHSYPPTWT (SEQ ID NO: 6).

4. The anti-IL-25 antibody according to claim 1, wherein the heavy chain variable region has at least 70%, such as at least 80%, for example at least 85%, such as at least 90% or more than 95% sequence identity with the amino acid sequence of SEQ ID NO: 12, and/or the light chain variable region has at least 70%, such as at least 80%, for example at least 85%, such as at least 90% or more than 95% sequence identity with the amino acid sequence of SEQ ID NO: 13.

5. The anti-IL-25 antibody according to claim 1, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 12, and/or the light chain variable region comprises the amino acid sequence of SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 13.

6. The anti-IL-25 antibody according to claim 5, wherein:

- i) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 7, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 10;
- ii) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 7, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 11;
- iii) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 8, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 10;
- iv) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 8, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 11;
- v) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 9, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 10;
- vi) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 9, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 11; or
- vii) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 13.

7. The anti-IL-25 antibody according to claim 1, which is a monoclonal antibody, and/or a murine, humanized or chimeric antibody, preferably of IgG class.